The Biosimilars Council, a division of the Association for Accessible Medicines, works to increase patient access to lifesaving, affordable biosimilar medicines. Leveraging our deep relationships on Capitol Hill, in federal agencies like FDA and CMS, and in the states, we strive to create a positive regulatory, reimbursement, political and policy environment to assure biosimilars thrive, providing billions in savings to patients and the health care system. Our members include biosimilar manufacturers and stakeholders working to promote biosimilar products in the U.S. market.
External link for Biosimilars Council
601 New Jersey Ave, NW
Suite 850
Washington, District of Columbia 20001, US
Biosimilars Council reposted this
Do not forget to register to our webinar "Streamlining the Regulatory Process to Advance Access to Biosimilars"! The webinar will focus on #Streamlining #Regulatory #Requirements to advance access to biosimilars and will feature expert discussions on the key barriers to biosimilar uptake in different regions and explore strategies to overcoming these obstacles. You can find the registration link here: https://lnkd.in/eQgBx7f3
Biosimilars Council reposted this
How can we improve access and affordability for safe, quality, and effective medicines and treatments? Join us 11/13 in DC or virtually from anywhere: https://lnkd.in/errXF72m #AtlanticMedicines is underwritten by by Association for Accessible Medicines.
Join us for this exciting webinar, moderated by our own Giuseppe Randazzo, with input from a global panel of experts--including Sarah Yim, Ali Alhomaidan Ph.D, Ivana Knezevic and Dr. Peter Richardson. Register to attend, here: https://lnkd.in/dVJaEPDY Skylar Jeremias FDA Medicines for Europe World Health Organization Association for Accessible Medicines The Center for Biosimilars #globalbiosimilarsweek
Join us for a special webinar presented by the IGBA - International Generic and Biosimilar medicines Association and hosted by The Center for Biosimilars, a media partner for #GlobalBiosimilarsWeek (#GBW) 2024. With an effort to highlight the importance of collaboration among #healthcareprofessionals, #patients, #stakeholders, and #policymakers, the webinar will focus on #Streamlining Regulatory Requirements to advance #AccessToBiosimilars and will feature expert discussions on the key #barriers to #biosimilar uptake in different regions and explore strategies to overcoming these obstacles. Register at: https://lnkd.in/eQgBx7f3
Biosimilars Council reposted this
November 13 in Washington, DC: Experts to discuss generics and biosimilars, and adapting to emerging health threats while continuing to provide affordable, high-quality medicines. Join #AtlanticMedicines: https://lnkd.in/errXF72m Underwritten by by Association for Accessible Medicines.
"During a fireside chat at the #GRxBiosims conference, Sarah Yim, MD, director of the FDA's Office of Therapeutic Biologics and Biosimilars (OTBB), stressed the need for stronger education efforts and industry collaboration to boost trust and streamline the path to biosimilar adoption." Read Skylar Jeremias full article for The Center for Biosimilars: Giuseppe Randazzo Sarah Yim Association for Accessible Medicines IGBA - International Generic and Biosimilar medicines Association
Biosimilars Council reposted this
Grateful for the the partnership and participation of FDA subject matter experts during this week’s #GRxBiosims event—including Dr. Jacqueline Corrigan-Curay, who left our 400+ attendees with these final thoughts: “Medicines only work if patients have access… the generic and biosimilar industries have made outstanding contrubutions to public health, by increasing access snd affordability.” Biosimilars Council
Dr. Jacqueline Corrigan-Curay, Principal Deputy Center Director in the Center for Drug Evaluation and Research, and Dr. Iilun Murphy, Director of the Office of Generic Drugs, will be speaking at the 2024 GRx+Biosims Conference on October 21, 2024. Their remarks will focus on how we can work together to help patients to get timely access to generic and biosimilar medicines, which may offer patients more affordable treatment options that are held to the same rigorous FDA quality standards. Updates and milestones from these FDA programs will also be shared. Dr. Robert Califf, Commissioner of Food & Drugs, and other FDA representatives will be also be participating. This event is being held by the Association for Accessible Medicines for the Accessible Medicines and Biosimilars Council.
“As the Food and Drug Administration (FDA) begins to deemphasize the interchangeability designation, with an eye towards making any approved #biosimilar interchangeable with the reference product, an expert panel at this week’s GRx+Biosims 2024 conference tackled the prevailing issue: Does #interchangeability matter today?” READ⬇️ Stan Mehr FDA Association for Accessible Medicines #GRxBiosims
“Our main priority is to streamline biosimilar development.” --Emanuela Lacana, PhD Depty Director, OTTB, OND, CDER, FDA #GRxBiosims Association for Accessible Medicines
"Interchangeability is a regulatory designation. With the FDA taking necessary steps to alleviate this, means we need legislation to step up as well." — Sonia Tadjalli Oskouei, PharmD, VP & U.S. Head, Biosimilars and Specialty, Sandoz #GRxBiosims Association for Accessible Medicines
“It is false and misleading to suggest that biosimilars are not as safe and effective as their reference products. We must address misinformation in the #biosimilars industry.” — Keren Haruvi Snir, Board Chair, Association for Accessible Medicines #GRxBiosims